Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors

American Journal of Clinical Pathology

Volumn 140, Issue 1, 2013, Pages 61-72

  Galván, Jose A ^a   Astudillo, Aurora ^b   Vallina, Aitana ^a   Fonseca, Paula J ^b   Gómez Izquierdo, Lourdes ^c   García Carbonero, Rocío ^d   González, Maria Victoria ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Servicio de Anatomia Patologica   (Spain)

^d Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

catenin; E cadherin; EMT; Foxc2; Neuroendocrine tumors; Snail1; Snail2

Indexed keywords

BETA CATENIN; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL1; TRANSCRIPTION FACTOR SNAIL2; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CELL MEMBRANE; DIFFERENTIAL DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME;

Β-CATENIN; E-CADHERIN; EMT; FOXC2; NEUROENDOCRINE TUMORS; SNAIL1; SNAIL2;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; SPAIN; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879430558     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPIV40ISTBXRAX     Document Type: Article

References (40)

1. Solcia E, Capella C, Fiocca R, et al. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am. 1989;18:671-693.
2. Kloppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(suppl 1):S9-S27.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
4. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Sterling, VA: Stylus; 2010.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev. 2002;2:442-454.
6. Thiery JP, Acloque H, Huang RY, et al. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871-890.
7. Thiery JP. Transitions epithelium mesenchyme dans le developpement et la progression des carcinomes [Epithelialmesenchymal transitions in cancer onset and progression]. Bull Acad Natl Med. 2009;193:1969-1979.
8. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154:8-20.
9. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest. 2009;119:1420-1428.
10. Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83.
11. Hemavathy K, Ashraf SI, Ip YT. Snail/Slug family of repressors: slowly going into the fast lane of development and cancer. Gene. 2000;257:1-12.
12. Mani SA, Yang J, Brooks M, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007;104:10069-10074.
13. Bolos V, Peinado H, Perez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(pt 3):499-511.
14. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927-939.
15. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci. 2005;118(pt 5):873-887.
16. Alexander NR, Tran NL, Rekapally H, et al. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res. 2006;66:3365-3369.
17. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184.
18. Batlle E, Sancho E, Franci C, et al. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84-89.
19. Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113:173-185.
20. Shimoyama Y, Hirohashi S, Hirano S, et al. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 1989;49:2128-2133.
21. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 2000;87:992-1005.
22. Wang GG, Yao JC, Worah S, et al. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol. 2005;18:1079-1087.
23. Kawahara M, Kammori M, Kanauchi H, et al. Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. Eur J Surg Oncol. 2002;28:140-146.
24. Wheelock MJ, Shintani Y, Maeda M, et al. Cadherin switching. J Cell Sci. 2008;121(pt 6):727-735.
25. Kashima T, Kawaguchi J, Takeshita S, et al. Anomalous cadherin expression in osteosarcoma: possible relationships to metastasis and morphogenesis. Am J Pathol. 1999;155:1549-1555.
26. Asano K, Kubo O, Tajika Y, et al. Expression of cadherin and CSF dissemination in malignant astrocytic tumors. Neurosurg Rev. 2000;23:39-44.
27. Poser I, Dominguez D, de Herreros AG, et al. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem. 2001;276:24661-24666.
28. Blanco MJ, Moreno-Bueno G, Sarrio D, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002;21:3241-3246.
29. Roy HK, Smyrk TC, Koetsier J, et al. The transcriptional repressor SNAIL is overexpressed in human colon cancer. Dig Dis Sci. 2005;50:42-46.
30. Rosivatz E, Becker KF, Kremmer E, et al. Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch. 2006;448:277-287.
31. Franci C, Takkunen M, Dave N, et al. Expression of Snail protein in tumor-stroma interface. Oncogene. 2006;25:5134-5144.
32. Galván JA, González MV, Crespo G, et al. Snail nuclear expression parallels higher malignancy potential in neuroendocrine lung tumors. Lung Cancer. 2010;69:289-295.
33. Fendrich V, Waldmann J, Esni F, et al. Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2007;14:865-874.
34. Jia H, Jiang X, Zhao Z, et al. High frequency of downregulation of E-cadherin detected in benign sporadic insulinomas by multiplex ligation-dependent probe amplification. Hum Pathol. 2009;40:1336-1341.
35. Kuroda N, Mizushima S, Guo L, et al. Goblet cell carcinoid of the appendix: investigation of the expression of β-catenin and E-cadherin. Pathol Int. 2001;51:283-287.
36. Li CC, Hirowaka M, Qian ZR, et al. Expression of E-cadherin, β-catenin, and Ki-67 in goblet cell carcinoids of the appendix: an immunohistochemical study with clinical correlation. Endocr Pathol. 2002;13:47-58.
37. Moller CJ, Christgau S, Williamson MR, et al. Differential expression of neural cell adhesion molecule and cadherins in pancreatic islets, glucagonomas, and insulinomas. Mol Endocrinol. 1992;6:1332-1342.
38. Zacharias J, Nicholson AG, Ladas GP, et al. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg. 2003;75:348-352.
39. Oberg K. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol. 2012;24:433-440.
40. Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719-731.